A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

NCT05548231 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of the drug LY3437943 in Chinese adults who are overweight or have obesity.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind basic-science study

Participants 32 people

Who can join Ages 20–65 · all sexes

Timeline Started 2022-10 · est. completion 2023-07

Where 2 sites · China

What this study is testing ClinicalTrials.gov NCT05548231 ↗

Description as written by the study sponsor.

The main purpose of this study is to learn about the safety and tolerability of LY3437943 when given to Chinese participants with overweight body mass index (BMI) or obesity. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin. For each participant, the study will last about 20 weeks excluding screening period and may include up to 20 visits to the study center.

Treatments tested

LY3437943 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Sponsor	Eli Lilly and Company
Conditions studied	Overweight, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05548231 ↗